Marketing right for SGLT2 inhibitor Apleway to be transferred from Sanofi to Kowa Medical Dialogues Bureau18 Feb 2020 7:23 AM GMTChugai and Sanofi agreed to terminate their license agreement. Kowa and Sanofi agreed that the marketing right for Apleway will be transferred from...